Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 10/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11660382 | 0.89 | HPGD (0.70) | TSHRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6579496 | 0.87 | SMN1; SMN2 (0.66) | TSHRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL29451289 | 0.87 | SMN1; SMN2 (0.66) | TSHRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6464089 | 0.86 | KMT2A (0.61) | TSHRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5534456 | 0.86 | KMT2A (0.66) | TSHRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL28918511 | 0.86 | SMN1; SMN2 (0.64) | TSHRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL528361 | 0.84 | HDAC1 (0.70) | TSHRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6005341 | 0.84 | GAA (0.69) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL28858859 | 0.83 | KMT2A (0.58) | TSHRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL10192134 | 0.83 | CYP1A2 (0.71) | TSHRMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015660-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-01-19 | — | — | US | disclosed |
| US-8168650-B2 | Therapeutic uses of bicyclic ligands of sigma 2 receptor | WASHINGTON UNIVERSITY (US) | 2012-05-01 | — | — | US | disclosed |
| US-8143222-B2 | Modular platform for targeted therapeutic delivery | WASHINGTON UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100048614-A1 | THERAPEUTIC USES OF BICYCLIC LIGANDS OF SIGMA 2 RECEPTOR | WASHINGTON UNIVERSITY (US) | 2010-02-25 | — | — | US | disclosed |
| US-7612085-B2 | Sigma 2 receptor ligands and therapeutic uses therefor | WASHINGTON UNIVERSITY (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090176705-A1 | MODULAR PLATFORM FOR TARGETED THERAPEUTIC DELIVERY | WASHINGTON UNIVERSITY (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080161343-A1 | Sigma 2 Receptor Ligands and Therapeutic Uses Therefor | WASHINGTON UNIVERSITY | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161343-A1 | Sigma 2 Receptor Ligands and Therapeutic Uses Therefor | SIGMAR1, TMEM97, BAD | TSHR 1299/4885MEN1 4512/4885KMT2A 2434/4885 |
| US-20170015660-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | SIGMAR1, TMEM97, AIFM2 | TSHR 204/4885MEN1 3626/4885KMT2A 3212/4885 |
| US-20100048614-A1 | THERAPEUTIC USES OF BICYCLIC LIGANDS OF SIGMA 2 RECEPTOR | SIGMAR1, TMEM97, BAD | TSHR 964/4885MEN1 4799/4885KMT2A 2541/4885 |
| US-20090176705-A1 | MODULAR PLATFORM FOR TARGETED THERAPEUTIC DELIVERY | SIGMAR1, TMEM97, CCAR2 | TSHR 640/4885MEN1 4666/4885KMT2A 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.